Spike protein 15-16 months post-acute infection? Patterson et al.: "Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection"

levels of both intermediate (CD14+, CD16+) & non-classical monocyte (CD14Lo, CD16+) significantly elevated in PASC patients up to 15 months post-acute infection vs healthy controls (P=0.002 & P=0.01)

Bottom line: they all lied to us, CDC, NIH, NIAID etc., Fauci, Francis Collins, Albert Bourla etc. and now it seems likely spike persists a long time and maybe life long from vaccine if it persists that long from infection. This is the issue and we just do not know. For how long and where? What are the long term implications? They devised the lipid-nano particle fatty ball that encases the mRNA and the mRNA itself in a way to evade the immune system and to be stable and to protect the mRNA, and to effectively get to the far regions of the body. They did not study it for the vaccine/injection/inoculation and this is where the FDA failed us. The FDA failed to demand the safety data from the vaccine makers. This helps explain long-COVID as the spike is the toxic business end of the virus, whether from natural infection or vaccine (spike along manufactured by our own cells). Spike persisting that long is a huge problem especially if it happens post injection.

SOURCE:

Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection

“The recent COVID-19 pandemic is a treatment challenge in the acute infection stage but the recognition of chronic COVID-19 symptoms termed post-acute sequelae SARS-CoV-2 infection (PASC) may affect up to 30% of all infected individuals. The underlying mechanism and source of this distinct immunologic condition three months or more after initial infection remains elusive. Here, we investigated the presence of SARS-CoV-2 S1 protein in 46 individuals. We analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC).

The levels of both intermediate (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were significantly elevated in PASC patients up to 15 months post-acute infection compared to healthy controls (P=0.002 and P=0.01, respectively). A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection. Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19 patients and 1 out of 26 PASC patients contained ddPCR+ peripheral blood mononuclear cells, however, only fragmented SARS-CoV-2 RNA was found in PASC patients. No full length sequences were identified, and no sequences that could account for the observed S1 protein were identified in any patient. That non-classical monocytes may be a source of inflammation in PASC warrants further study.”